Updates in the Management of Stage III Non-Small Cell Lung Cancer (NSCLC) - Episode 1

Patient with Stage IIIB NSCLC with No Actionable Mutations and PD-L1 TPS 0%

, , ,

Medical experts discuss a specific case for a patient diagnosed with stage IIIB NSCLC.

Now Viewing
EP. 1: Patient with Stage IIIB NSCLC with No Actionable Mutations and PD-L1 TPS 0%
EP. 2: Biomarker Testing and the Multidisciplinary Approach in Early-Stage NSCLC
EP. 3: Navigating Neoadjuvant and Perioperative Treatment Strategies in Early Stage NSCLC
EP. 4: Treatment Considerations for Neoadjuvant and Perioperative Therapy in ES NSCLC
EP. 5: Management of Borderline Resectable NSCLC
EP. 6: Management of Resectable Early Stage NSCLC with Actionable Mutations
EP. 7: Considerations for Combination of Adjuvant Chemotherapy and Targeted Therapy in Resectable ES NSCLC
EP. 8: Patient with Unresectable Stage IIIB EGFR-Mutant NSCLC with N2 Bulky Disease
EP. 9: Expert Perspectives on Patient Selection for cCRT and sCRT in Unresectable ES NSCLC
EP. 10: Treatment Considerations for Consolidation Durvalumab in Unresectable ES NSCLC

Video content above is prompted by the following:

  • Briefly provide comments and perspectives on this patient case.
  • Briefly comment on your approach to biomarker testing in patients with potentially resectable NSCLC?
    • What type of testing do you recommend? (e.g., single biomarker EGFR vs NGS)
    • How are you using biomarker testing pre- and post-surgery?
  • How do you determine eligibility for surgical resection in patients with Stage III NSCLC at your practice and what factors influence patient selection for available surgical procedures? (e.g. mediastinoscopy, EBUS, lobectomy)